Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00184366|
Recruitment Status : Terminated (efalizumab was withdrawn from market; full 2 years follow-up only 14 patients)
First Posted : September 16, 2005
Last Update Posted : January 19, 2012
The main objectives of the project are:
- To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)
- To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.
|Condition or disease||Intervention/treatment|
|Plaque Psoriasis||Drug: efalizumab|
This is an investigator initiated,prospective, longitudinal, observation study. Before starting treatment with efalizumab we will record factors such as demographic data, type of psoriasis, previous treatment, other diseases etc.
We will follow the patients and classify them as responders and non-responders. We hope to find 4-5 factors which we can use later to predict response of this drug.
|Study Type :||Observational|
|Actual Enrollment :||96 participants|
|Official Title:||Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||July 2008|
- Response PASI 75 [ Time Frame: 2 years ]
- Dermatology Life Quality index (DLQI) [ Time Frame: 2 years ]
- Psoriasis disability Index (PDI) [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184366
|Dep of dermatology, St Olavs Hospital|
|Trondheim, Norway, 7006|
|Study Chair:||Morten Dalaker, univ lekt II||St Olavs hospital, NTNU, Norway|